Aoxing Pharma, a China company with a narcotic drugs focus, received an SFDA license to produce the API in pholcodine, an opioid cough suppressant. The company still needs to pass a GMP inspection before it is allowed to market the product. Aoxing owns one of just thirteen narcotics licenses in China. Nevertheless, the company’s revenues for the most recent 12 months were only $9 million, while its loss totaled $15 million. More details.... Stock Symbol: (NYSE MKT: AXN) Share this with colleagues: // //